Molecular modeling and biological studies show that some μ-opioid receptor agonists might elicit analgesia acting as MMP-9 inhibitors
Aim: Despite the serious side effects, analgesics acting on opioid receptors are still considered the best way to get antinociception. Matrix metalloproteinases, a large family of zinc-dependent proteases implicated in many pathological conditions, such as diabetes and osteoarthritis, are also involved in inflammation and pain. Methodology & results: Looking for evidence of possible interactions of opioid pathways and inflammation mediators, molecular modeling studies of a series of recently developed μ-opioid receptor benzomorphanic agonists together with biological data on pain and inflammation molecular targets, allowed us to hypothesize a possible correlation between μ-opioid receptor system and MMP-9. Conclusion: A new compound, (-)-MML1017, emerged as a possible dual-acting agent able to interact selectively and potently with the two molecular targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 11 vom: 01. Juni, Seite 1245-1258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ronsisvalle, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.05.2020 Date Revised 26.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2018-0535 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295959789 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295959789 | ||
| 003 | DE-627 | ||
| 005 | 20231225084810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0535 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0986.xml |
| 035 | |a (DE-627)NLM295959789 | ||
| 035 | |a (NLM)30974972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ronsisvalle, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular modeling and biological studies show that some μ-opioid receptor agonists might elicit analgesia acting as MMP-9 inhibitors |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2020 | ||
| 500 | |a Date Revised 26.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Despite the serious side effects, analgesics acting on opioid receptors are still considered the best way to get antinociception. Matrix metalloproteinases, a large family of zinc-dependent proteases implicated in many pathological conditions, such as diabetes and osteoarthritis, are also involved in inflammation and pain. Methodology & results: Looking for evidence of possible interactions of opioid pathways and inflammation mediators, molecular modeling studies of a series of recently developed μ-opioid receptor benzomorphanic agonists together with biological data on pain and inflammation molecular targets, allowed us to hypothesize a possible correlation between μ-opioid receptor system and MMP-9. Conclusion: A new compound, (-)-MML1017, emerged as a possible dual-acting agent able to interact selectively and potently with the two molecular targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a MMP-9 inhibitors | |
| 650 | 4 | |a MOR agonists | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a molecular modeling | |
| 650 | 4 | |a multitarget drugs | |
| 650 | 4 | |a pain | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Benzomorphans |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase Inhibitors |2 NLM | |
| 650 | 7 | |a Receptors, Opioid, mu |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.35 |2 NLM | |
| 700 | 1 | |a Spadaro, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasello, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Basile, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Panarello, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Franchini, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Renis, Marcella |e verfasserin |4 aut | |
| 700 | 1 | |a Guccione, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Crascì, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Panico, Anna Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 11(2019), 11 vom: 01. Juni, Seite 1245-1258 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:11 |g day:01 |g month:06 |g pages:1245-1258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2018-0535 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 11 |b 01 |c 06 |h 1245-1258 | ||